---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-018789"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:47:09.337303+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Allarity Therapeutics amends convertible notes to cap conversion at 19.9% without stockholder approval

## Summary
- Amendment dated Feb 27, 2024 between Allarity and holder 3i, LP modifies two senior convertible notes from Jan and Feb 2024.
- New provision bars conversion or share issuance if it would exceed 19.9% of outstanding common stock absent stockholder approval.
- All other terms of the Notes remain in full force and effect.
- Company also furnished an updated corporate presentation on its website (no specific material details provided in this filing).

## SEC filing metadata
- accession: 0001213900-24-018789
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390024018789/0001213900-24-018789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390024018789/ea0200995-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-018789
- JSON: https://secwatch.observer/filing/0001213900-24-018789.json
- Plain text: https://secwatch.observer/filing/0001213900-24-018789.txt

## Key facts
- Material Agreements
  Allarity Therapeutics, Inc. amended Amendment to Senior Convertible Notes with 3i, LP (effective 2024-02-27).
  - Action: amendment
  - Agreement: notes offering
  - Counterparty: 3i, LP
  - Effective: 2024-02-27
  source text: On February 27, 2024, Allarity Therapeutics, Inc., a Delaware corporation (“we,” “our,” or the “Company”) and 3i, LP, a Delaware limited partnership, (the “Holder” and together with us, the “Parties”) entered into an Amendment to Senior Convertible Notes (the “Amendment”) to two senior convertible notes dated as of January 18, 2024 and February 13, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390024018789/0001213900-24-018789-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.